Alzheimer Disease & Dementia

This one-of-a-kind Alzheimer disease treatment targets the amyloid beta plaques in the brain, potentially slowing cognitive decline.

Sleep problems are understudied, underdiagnosed, and undertreated.

Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.

CRL cites lack of substantial evidence of efficacy needed for approval.

This monoclonal antibody showed significant slowing of decline in patients with Alzheimer disease.

Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.

About 2.4 million people in the US experience dementia related psychosis, yet only half ever receive a diagnosis.

Handling aggression in patients with dementia can be difficult...

What dementia treatment makes an interesting appearance in classical literature?

Cognitive disorders are varied and complicated, and require a close eye...

A study on a new Alzheimer disease vaccine lacks concrete numbers.

Cognitive impairment is not always associated with dementia. For this reason, a full comprehensive history is an integral component of any assessment. Take the quiz to learn more.

What consequences will big data and artificial intelligence have on brain health and economics?

A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.

A new treatment for hallucinations and delusions in individuals with Alzheimer disease may be on the horizon.

New developments in Alzheimer disease treatment and research.

The Lumipulse® G β-Amyloid Ratio in vitro diagnostic test was filed for 510(k) premarket clearance.

A new study associates a gene that facilitates neuron communication in the nervous system with memory loss.

Telehealth poses challenges for patients, clinicians, families, and caregivers.

Patients with chronic inflammatory diseases, especially rheumatoid arthritis, are at 800% increased risk for developing Alzheimer disease compared to the general population. A new treatment is in the works to combat this inflammation.

Good news in the fight against Alzheimer disease, with major progress in new, innovative treatments.

Often misdiagnosed as other psychiatric disorders, FTD is the third most common type of dementia and the second most common among patients 65 years or younger. How to spot the signs.

Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.

According to some estimates, nearly 2.3 million people in the US suffer from dementia-related psychosis. The Gerontological Society of America’s diagnostic and treatment considerations help shed light on this complicated condition.

How do you determine whether pain is present and its severity as well as how it responds to treatment in patients who are cognitively impaired? Some answers to these questions.